Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Gains from Investment Securities: 2021-2022

Historic Gains from Investment Securities for Atea Pharmaceuticals (AVIR) over the last 2 years, with Dec 2022 value amounting to $2.9 million.

  • Atea Pharmaceuticals' Gains from Investment Securities rose 32.81% to $2.9 million in Q1 2022 from the same period last year, while for Dec 2021 it was $10.5 million, marking a year-over-year change of. This contributed to the annual value of $2.9 million for FY2022, which is 72.06% down from last year.
  • Per Atea Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $2.9 million for FY2022, which was down 72.06% from $10.5 million recorded in FY2021.
  • In the past 5 years, Atea Pharmaceuticals' Gains from Investment Securities registered a high of $10.5 million during FY2021, and its lowest value of $2.9 million during FY2022.
  • Moreover, its 2-year median value for Gains from Investment Securities was $6.7 million (2021), whereas its average is $6.7 million.
  • Data for Atea Pharmaceuticals' Gains from Investment Securities shows a maximum YoY crashed of 72.06% (in 2022) over the last 5 years.
  • Yearly analysis of 2 years shows Atea Pharmaceuticals' Gains from Investment Securities stood at $10.5 million in 2021, then tumbled by 72.06% to $2.9 million in 2022.